The administration's focus on rate review may have had a trickledown effect on states.
While many states already have been active in the oversight of insurer premiums and profits, seven states have increased their authority in the area. The scope of HHS' new authority and ongoing state action is likely to have a significant impact.
HHS announced in July 2011 that six states did not meet its criteria for an "effective rate review program"-Alabama, Arizona, Louisiana, Missouri, Montana and Wyoming. Thus, in these states, HHS is responsible for reviewing all proposed increases greater than 10%. HHS will conduct reviews for certain product lines in several other states until the states increase their authority.
HHS found the proposed increases to be unreasonable, based on the explanations and data provided by the insurers. In January, HHS explained that its determination was based on its finding that "the insurer would be spending a low percent of premium dollars on actual medical care and quality improvements, and because the justifications were based on unreasonable assumptions."
Although it generates attention, HHS cannot preclude the increases from going into effect. Instead, it has called on the insurers to rescind the rates, issue refunds or publicly explain their refusal to do so. Some states do have the power to prevent the increases, so HHS does not step in to do rate review.
MAINE ACTION
Over the past several years, the Maine Superintendent of Insurance has been engaged in a series of battles with an insurer regarding the state's oversight of rates. Maine law requires that health insurance rates not be "excessive, inadequate or unfairly discriminatory" and empowers the state to block any increases that violate the standard. In 2009, the superintendent denied the insurer's requested 18% rate increase because she determined that the rates were excessive and discriminatory, and instead declared that she would approve rates at a 10.9% average increase, which reduced the insurer's profit margin from 3% to 0%.
Similar battles ensued for proposed rate increases in 2010 and 2011, which resulted in the superintendent's imposition of profit margins of 0.5% and 1%, respectively. The insurer has challenged the scope of the Superintendent's authority in a lawsuit that has finally reached Maine's highest court. The court heard oral arguments in November and no decision has been issued. However, the result will likely have far-reaching effects on other states' interest in enforcing or expanding their authority.
Based on these recent federal and state actions, there is little doubt that the oversight of health insurance premiums is undergoing significant changes and shape-shifting that may not solidify anytime soon.
This column is written for informational purposes only and should not be construed as legal advice.
Laura McBride is an associate in the Litigation practice of Calfee, Halter & Griswold LLP.
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Phase 3 Trials of Oral Povorcitinib Show Positive Results in Hidradenitis Suppurativa
March 24th 2025A new drug application for povorcitinib is expected to be filed in late 2025 to early 2026 to treat adult patients with moderate to severe hidradenitis suppurativa, a chronic and painful inflammatory skin condition.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
2 Commerce Drive
Cranbury, NJ 08512